CD274 and diffuse large B-cell lymphoma: Currently available data on blocking PD-1/PD-L1 in non-selected DLBCL patients have been disappointing so far, but PD-1 inhibitors have been very successful in treating patients with R/R PMBL, leading to their rapid approval by the FDA.